Healing & repair
One chain. Three things the literature treats as interchangeable. The intact 43-mer holds G-actin. The first four residues, once clipped, are Ac-SDKP. Residues 17–23 are what gets bottled as TB-500.
The left side is the sequestered monomer. The right side is the filament a cell builds after that monomer is released. The map underneath marks the two fragments that have their own names.
43 residues
Binds one G-actin monomer and keeps it out of the filament until the cell moves.
Residues 1–4
Clipped from the N-terminus. This is the peptide in the fibrosis and NF-κB papers.
Residues 17–23
The LKKTETQ actin motif, synthesized on its own. It does not include Ac-SDKP.
Platelets carry a large store of thymosin β4. In culture and in rodent wounds, adding the full peptide speeds re-epithelialization and new-vessel growth. The usual reading is cytoskeletal: more monomer on hand, faster actin assembly at the leading edge. Corneal and dermal models are the cleanest of these. Cardiac injury models exist and are still preclinical.
Ac-SDKP is generated when prolyl oligopeptidase cuts the acetylated N-terminus. Its papers track NF-κB, TGF-β, and collagen in heart and kidney. That is a different experiment from “cells migrate faster.” Citing a fibrosis result as evidence for TB-500 swaps the molecule.
Human evidence is early wound studies, not an approved indication. Sport authorities prohibit thymosin β4 and the fragment together. Neither fact is a potency claim.
A 43-residue acetylated chain and a 7-residue motif are both sold under names that collapse into “TB-500.” The certificate should print the sequence. If it says LKKTETQ, you have the motif. If it lists the 43-mer beginning SDKP, you have thymosin β4. Mass and acetylation status belong on that same page — the acetyl group is part of the endogenous protein.